Quantcast

Latest Mylan Stories

2014-08-28 12:29:56

PITTSBURGH, Aug. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration (FDA). This product is the generic version of Teva's Copaxone® 40 mg/mL, which is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS)....

2014-08-27 12:30:03

LYNDHURST N.J. and NINGBO, China, Aug. 27, 2014 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") and the Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market. Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen to commercialize in the United States. Menovo will be...

2014-08-25 08:28:25

SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Thesan Pharmaceuticals announced today the appointment of Bhaskar Chaudhuri Ph.D., to its Board of Directors. Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming...

2014-08-22 08:24:49

PITTSBURGH, Aug. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic...

2014-08-18 12:27:41

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "The Overveiw of Japanese Generic Drug Market" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 This report talks about the overview of Japanese generic drug market. It gives the readers ann understanding of the overall climate surrounding generic market in Japan. The report covers related regulations, generics's share in Japan, market size, primary makers, market trend,...

2014-08-11 08:28:44

PITTSBURGH, Aug. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.(1) CEO...

2014-08-07 12:28:30

DUBLIN, Aug. 7, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Transdermal Drug Delivery Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal...

2014-08-05 04:21:28

EATONTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") has signed an Exclusive Development, Supply & Distribution Agreement with Dexcel Ltd. ("Dexcel") for an Extended Release ANDA drug product. Dexcel will be responsible for the development, registration and manufacturing of the product, and Heritage Pharmaceuticals will be responsible for marketing and distribution in the U.S. The product generates generic annual U.S. sales of approximately $60...

2014-07-23 08:30:32

District Court Judge Orders Apotex to Immediately Recall the Authorized Generic from its Direct Customers and to Stop Selling and Supplying the Product PITTSBURGH, July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil(®)...

2014-07-17 08:28:43

PITTSBURGH, July 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline (GSK) in relation to Paroxetine CR, the generic version of GSK's Paxil(®) CR. GSK is now precluded from supplying product to Apotex, which marketed the product as an authorized generic. Mylan had previously been awarded damages in the amount of $106,700,000 by the District...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related